RESUMEN
AIM:To determine whether there was a significant relationship between eye iris color with axial length, intraocular pressure, retinal nerve fiber layer (RNFL) thickness, macular thickness and choroidal thickness.METHODS:A prospective cross-sectional study involving 92 eyes of 92 healthy volunteers.These were divided into dark colored-eye (DCE) and light-colored eye (LCE) groups according to iris color.The RNFL and macular thicknesses were analysed with standard optical coherence tomography (OCT) protocol while choroidal thickness was analysed with electronic data interchange (EDI) protocol in all subjects.Choroidal thickness was measured at the fovea, 1500 μm nasal and 1500 μm temporal to the fovea in a horizontal section.RESULTS:Of the 92 eyes included, 62 (67.4%) were dark-colored while 30 (32.6%) were light-colored.The mean age was 29.22±5.86y in the subjects with DCE and 28.86±6.50y in those with LCE.No significant difference was detected in mean age, axial length, macular thickness, choroidal thickness and intraocular pressure (IOP) between the groups (P>0.05).However, RNFL thicknesses varied depending on the quadrant measured, and were lower in both global and the nasal and temporal quadrants for individuals with LCE (P≤0.022).CONCLUSION:No significant differences were found in IOP, macular thickness and choroid thickness between individuals with DCE and LCE.Meanwhile, the RNFL thickness is lower.
RESUMEN
AIM:To evaluate the potential posterior segment effects of topical application of brimonidine-purite 0.15％ through measurement of choroidal thickness (CT) in healthy eyes using enhanced depth imaging spectraldomain optical coherence tomography (EDI-SD-OCT).METHODS:Thirty-two eyes of 32 healthy subjects were included in this prospective,placebo controlled interventional clinical trial.They received one drop of topical preservative-free artificial tears as placebo for the first day and one drop of brimonidine-purite 0.15％ for the second day.Intraocular pressure,ocular perfusion pressure (OPP),and EDI-SD-OCT were performed at baseline,at 1,3 and 5h after the treatments.RESULTS:Compared to the measurements obtained at baseline,the CT measurements obtained after the topical application of brimonidine-purite 0.15％ significantly increased at the sub-fovea (P=0.001),at temporal 1500 μm to the fovea (P=0.003) and at nasal 1500 μm to the fovea (P=0.003).Choroidal thickness was unchanged in placebo group during the study (P ＞0.05).There was no significant reduction in the OPP in both groups (P ＞0.05).There were no adverse events during the study.CONCLUSIONS:Contrary to expectations,topical administration of brimonidine-purite 0.15％ resulted with thickening of sub-foveal,temporal and nasal CT.This might be related to altered auto-regulation mechanisms in choroidal vessels.
RESUMEN
ABSTRACT Purpose: Evaluation of the nerve fiber thicknesses of the macula, choroid, and retina using the apnea-hypopnea index in individuals with obstructive sleep apnea syndrome (OSAS) without systemic components. Methods: Prospective, controlled study. The central macular, choroidal, and retinal nerve fiber layer (RNFL) thicknesses were evaluated using enhanced depth imaging-spectral domain optical coherence tomography in individuals with OSAS. In people with severe OSAS who had received treatment, posterior ocular structures were examined over 3 months (4th and 12th weeks), and changes were evaluated. Only the right eyes of the participants were evaluated in the study. Results: A total of 72 people were involved in the study, with 18 in the control group and 19 with mild, 16 with moderate, and 19 with severe OSAS. No significant difference was found among the groups in terms of demographic measures. No significant differences were found among the groups in terms of the measures of central macular, central subfoveal choroidal (CSCT), temporal choroidal, nasal choroidal, and RNFL thicknesses. In severe OSAS cases in which treatment was administered, although subjective clinical recovery was observed, statistically significant thinning was detected during the 3-month follow-up period in the CSCT, general RNFL, as well as in the inferior and superior nasal quadrants, and temporal superior quadrant (p=0.005, p=0.009, p=0.039, p=0.003, and p=0.02, respectively). Conclusion: In the group with severe OSAS, thinning in some posterior ocular tissues was observed. Although patients with severe OSAS may experience clinical recovery, we recommend that they would be followed up in terms of ocular ischemic injury.
RESUMO Objetivo: Avaliação de espessuras das fibras nervosas da mácula, coroide e da retina de acordo com os índices de apnéia e hipopnéia (AHI) em indivíduos com síndrome da apneia obstrutiva do sono (OSAS), sem componentes sistêmicos. Métodos: Estudo prospectivo, controlado. As espessuras centrais maculares, da coroide e da camada de fibras nervosas da retina foram avaliadas tomografia de coerência óptica de domínio espectral de profundidade aprimorada em indivíduos com síndrome da apneia obstrutiva do sono. Em pessoas com OSAS grave a quem foi aplicado o tratamento, estruturas oculares posteriores foram examinados por três meses (4ª e 12ª semanas) e as alterações foram avaliadas. Apenas os olhos direitos dos participantes foram envolvidos no estudo. Resultados: 72 pessoas foram envolvidas no estudo, 18 no grupo controle e, 19 com OSAS leve, 16 com OSAS moderada e 19 com OSAS grave. Não houve diferença significativa entre os grupos em relação às medidas demográficas. Não houve diferenças significativas estavam presentes entre os grupos em termos de medidas de espessura macular central (CMT), espessura subfoveal central da coroide (CSCT), espessura da coroide temporal (TCT), espessura da coroide nasal (NCT) e, a camada de fibras nervosas da retina (RNFL). Em casos de OSAS graves onde o tratamento foi aplicado, apesar de ter sido observada recuperação clínica subjetiva, detectou-se afinamento estatisticamente significativo durante os três meses de acompanhamento, em CSCT, RNFL geral, quadrantes nasais inferior e superior, e quadrante temporal superior (p=0,005, p=0,009, p=0,039, p=0,003, p=0,02). Conclusão: No grupo com OSAS grave, foi observado afinamento em algumas áreas posteriores dos tecidos oculares. Embora os pacientes com OSAS grave possam apresentar recuperação clínica, recomendamos que eles sejam seguidos em termos de lesão isquêmica ocular.